|
AOTI Inc on Wednesday said the National Institute for Health & Care Excellence, NICE, has included the firm’s topical wound oxygen therapy on the Advanced Wound Care framework. The Oceanside, California-based wound healing-focused medical technology company said the updated NICE guidelines include topical oxygen therapy as an adjunct to standard care for diabetic foot ulcers that are not responding to treatment. AOTI Chief Executive Officer Mike Griffiths said: ‘With TWO2 therapy now on the NHS framework and with its inclusion in the NICE treatment guidelines, patients in England have access to its sustained healing benefits, helping to reduce the burden on strained national healthcare resources while delivering substantial quality of life benefits for patients at home. In addition to these meaningful clinical improvements, recently published health economic research has demonstrated that broad adoption of TWO2 therapy within the NHS would significantly lower overall diabetic foot care costs. ‘This recognition by another of Europe’s leading healthcare bodies is consistent with the recent G-BA recommendation in Germany and is ahead of our expectations. Such continued positive decisions only further validates our clinical and value proposition supporting a positive coverage determination by Centers for Medicare & Medicaid Services in the US.’ AOTI shares rose 4.4% to 57.44 pence each on Wednesday afternoon in London. Copyright 2025 Alliance News Ltd. All Rights Reserved.
|
